Public Preferences for a COVID-19 Vaccination Program in Quebec: A Discrete Choice Experiment

Morillon, Gabin F; Poder, Thomas G.

doi:10.1007/s40273-021-01124-4

Cited by 7 publications

(26 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most studies used samples of adults ( N = 26). Sixteen studies addressed vaccine hesitancy (i. e., doubts concerning the reception of a COVID‐19 vaccine) 6 , 7 , 8 , 16 , 17 , 29 , 33 , 34 , 37 , 39 , 44 , 45 , 46 , 47 , 48 , 50 and 14 studies explored vaccine unwillingness (i.e., the likelihood of refusing a COVID‐19 vaccine). 28 , 30 , 32 , 35 , 36 , 38 , 40 , 41 , 42 , 43 , 46 , 49 , 51 , 52 The characteristics of the studies are presented in Table 1 .…”

Section: Resultsmentioning

confidence: 99%

“…Vaccine hesitancy was related to a lower educational level in five studies. 6 , 16 , 33 , 39 , 44 More specifically, people with an education of high school or less were more hesitant, 16 that is, people with a bachelor's degree or more were less hesitant. 39 The willingness to accept a vaccine was related to higher levels of education, more specifically with having a postsecondary degree or higher in six studies.…”

Section: Resultsmentioning

confidence: 99%

“…Vaccine hesitancy was reported to be related to several factors including concerns that receiving a vaccine has more risks than benefits, 6 , 29 fear of side effects, 6 , 39 , 47 belief that insufficient research had been conducted on the vaccine, 29 , 47 , 48 mistrust in vaccines, 8 , 39 , 44 insufficient time to reflect on accepting the vaccine, 8 having an incomplete vaccination history, 16 , 29 , 33 believing that COVID‐19 will not affect the person or the people around them, 6 , 16 , 29 , 44 living in rural areas, 50 holding more conservative political views, 6 and poorer executive functions. 34 …”

Section: Resultsmentioning

confidence: 99%

“…Results on vaccine hesitancy according to sex indicated that women were more hesitant than men in five studies. 8,16,44,45,50 However, in three studies, researchers found no sex differences. 6,7,17 Among four studies with information on vaccine willingness and biological sex, men tended to be more willing to receive a COVID-19 vaccination compared with women.…”

Section: Gendermentioning

confidence: 93%

See 3 more Smart Citations

Prevalence and factors related to COVID‐19 vaccine hesitancy and unwillingness in Canada: A systematic review and meta‐analysis

Cénat

Noorishad

Farahi

et al. 2022

Journal of Medical Virology

View full text Add to dashboard Cite

This systematic review and meta‐analysis examined the prevalence and factors associated with vaccine hesitancy and vaccine unwillingness in Canada. Eleven databases were searched in March 2022. The pooled prevalence of coronavirus disease 2019 (COVID‐19) vaccine hesitancy and unwillingness was estimated. Subgroup analyses and meta‐regressions were performed. Out of 667 studies screened, 86 full‐text articles were reviewed, and 30 were included in the systematic review. Twenty‐four articles were included in the meta‐analysis; 12 for the pooled prevalence of vaccine hesitancy (42.3% [95% CI, 33.7%–51.0%]) and 12 for vaccine unwillingness (20.1% [95% CI, 15.2%−24.9%]). Vaccine hesitancy was higher in females (18.3% [95% CI, 12.4%−24.2%]) than males (13.9% [95% CI, 9.0%−18.8%]), and in rural (16.3% [95% CI, 12.9%−19.7%]) versus urban areas (14.1% [95%CI, 9.9%−18.3%]). Vaccine unwillingness was higher in females (19.9% [95% CI, 11.0%−24.8%]) compared with males (13.6% [95% CI, 8.0%−19.2%]), non‐White individuals (21.7% [95% CI, 16.2%−27.3%]) than White individuals (14.8% [95% CI, 11.0%−18.5%]), and secondary or less (24.2% [95% CI, 18.8%−29.6%]) versus postsecondary education (15.9% [95% CI, 11.6%−20.2%]). Factors related to racial disparities, gender, education level, and age are discussed.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Gendermentioning

confidence: 93%

See 2 more Smart Citations

Prevalence and factors related to COVID‐19 vaccine hesitancy and unwillingness in Canada: A systematic review and meta‐analysis

Cénat

Noorishad

Farahi

et al. 2022

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

“…A DCE study for elicit preferences of the Quebec population toward a COVID-19 vaccination program found effectiveness, side effects, the duration of the protective effect, and the origin of the vaccine were the most preferred attributes [ 26 ]. This study supports our findings.…”

Section: Discussionmentioning

confidence: 99%

Public Preferences and Willingness to Pay for a COVID-19 Vaccine in Iran: A Discrete Choice Experiment

Darrudi

Daroudi

Yunesian

et al. 2022

PharmacoEconomics Open

View full text Add to dashboard Cite

Background and objective The coronavirus disease 2019 (COVID-19) pandemic is a major international threat and vaccination is the most robust strategy to terminate this crisis. It is helpful for policymakers to be aware of community preferences about vaccines. The present study aims to investigate the public’s preferences and willingness to pay for the COVID-19 vaccine in Iran. Methods This research is a cross-sectional study performed using a discrete choice experiment for a sample of the public population of several provinces of Iran in 2021. The samples were divided into two groups: one group expressed their preferences regarding the vaccine’s attributes, and another group expressed their preferences regarding prioritizing individuals to get the vaccine. The discrete choice experiment design included five attributes including effectiveness, risk of severe complications, price, location of vaccine production, and duration of protection related to preferences for vaccine selection and six attributes including age, underlying diseases, employment in the healthcare sector, the rate of virus spread, the necessary job, and cost to the community related to preferences for prioritizing individuals to get the vaccine. A total of 715 individuals completed the questionnaire. The conditional logit regression model was used to analyze the discrete choice experiment data. Willingness to pay for each attribute was also calculated. Results The willingness to pay for the COVID-19 vaccine with 90% (70%) efficacy, the risk of severe complications for 1 (5) person per one million people, imported (domestic) vaccine, and 24-month (12-month) duration of protection attributes was about US$71 (US$37). The preference for vaccination for respondents was enhanced by increasing the efficacy and the duration of vaccine protection and decreasing complications and costs. The likelihood of prioritizing individuals to get a vaccination was increased for a person with an underlying disease, employment in the healthcare sector, the necessary job for the community, the high potential for virus spread in the community, and the high cost of death to the community. The age variable was not statistically significant for prioritizing individuals to get the vaccine. Conclusions In the setting of the COVID-19 vaccination program, the public’s preferences identified in this study should be considered. The obtained results provide useful information for policymakers to identify individual and social values for an appropriate vaccination strategy. Supplementary Information The online version contains supplementary material available at 10.1007/s41669-022-00359-x.

show abstract

Jumping the Queue:Willingness to Pay for Faster Access to COVID-19 Vaccines in Seven European Countries

Neumann-Böhme

Sabat

Brinkmann³

et al. 2023

PharmacoEconomics

View full text Add to dashboard Cite

Introduction Given the initial shortage of vaccines to protect against coronavirus disease 2019 (COVID-19), many countries set up priority lists, implying that large parts of the population had to wait. We therefore elicited the willingness to pay (WTP) for access to two hypothetical COVID-19 vaccines. Methods Respondents were asked how much they would be willing to pay to get an immediate COVID-19 vaccination rather than waiting for one through the public system. We report data collected in January/February 2021 from the European COVID Survey (ECOS) comprising representative samples of the population in Denmark, France, Germany, Italy, Portugal, the Netherlands, and the UK ( N = 7068). Results In total, 73% (68.5%) of respondents were willing to pay for immediate access to a 100% (60%) effective vaccine, ranging from 66.4% (59.4%) in the Netherlands to 83.3% (81.1%) in Portugal. We found a mean WTP of 54.36 euros (median 37 euros) for immediate access to the 100% effective COVID-19 vaccine and 43.83 euros (median 31 euros) for the 60% effective vaccine. The vaccines’ effectiveness, respondents’ age, country of residence, income, health state and well-being were significant determinants of WTP. Willingness to be vaccinated (WTV) was also strongly associated with WTP, with lower WTV being associated with lower WTP. A higher perceived risk of infection, higher health risk, more trust in the safety of vaccines, and higher expected waiting time for the free vaccination were all associated with a higher WTP. Conclusion We find that most respondents would have been willing to pay for faster access to COVID vaccines (jumping the queue), suggesting welfare gains from quicker access to these vaccines. This is an important result in light of potential future outbreaks and vaccines. Supplementary Information The online version contains supplementary material available at 10.1007/s40273-023-01284-5.

show abstract

Public Preferences for a COVID-19 Vaccination Program in Quebec: A Discrete Choice Experiment

Cited by 7 publications

References 67 publications

Prevalence and factors related to COVID‐19 vaccine hesitancy and unwillingness in Canada: A systematic review and meta‐analysis

Prevalence and factors related to COVID‐19 vaccine hesitancy and unwillingness in Canada: A systematic review and meta‐analysis

Public Preferences and Willingness to Pay for a COVID-19 Vaccine in Iran: A Discrete Choice Experiment

Jumping the Queue:Willingness to Pay for Faster Access to COVID-19 Vaccines in Seven European Countries

Contact Info

Product

Resources

About